Evidence map›Paper›PMID 32681604›Full record

ArticleChemMedChem2020

Optimization of 4-Substituted Benzenesulfonamide Scaffold To Reverse Acinetobacter baumannii Serum-Adaptive Efflux Associated Antibiotic Tolerance.

Michaelle Chojnacki, Xufeng Cao, Mikaeel Young, Rebecca N Fritz, Paul M Dunman, Daniel P Flaherty

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Genetic Determinants ofAntibiotics (Basel, Switzerland) · 2023
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Michaelle ChojnackiDepartment of Microbiology and Immunology, University of Rochester Medical Center, 601 Elmwood Ave., Rochester, NY, 14642, USA.
Xufeng CaoDepartment of Medicinal Chemistry and Molecular Pharmacology College of Pharmacy, Purdue University, 575 Stadium Mall Dr., West Lafayette, IN, 47907.
Mikaeel YoungDepartment of Microbiology and Immunology, University of Rochester Medical Center, 601 Elmwood Ave., Rochester, NY, 14642, USA.
Rebecca N FritzDepartment of Medicinal Chemistry and Molecular Pharmacology College of Pharmacy, Purdue University, 575 Stadium Mall Dr., West Lafayette, IN, 47907.
Paul M DunmanDepartment of Microbiology and Immunology, University of Rochester Medical Center, 601 Elmwood Ave., Rochester, NY, 14642, USA.
Daniel P FlahertyDepartment of Medicinal Chemistry and Molecular Pharmacology College of Pharmacy, Purdue University, 575 Stadium Mall Dr., West Lafayette, IN, 47907.ORCID 0000-0002-8305-0606
Purdue University West Lafayette · USUniversity of Rochester Medical Center · US

Funding

Project 2: Defining the Protective vs. Susceptible Immune Proteome of S. aureus OsteomyelitisP50AR072000 · NIAMS · UNIVERSITY OF ROCHESTER · PI Edward M. Schwarz · 2017 to 2026
$13.6M
Training Program in Oral ScienceT90DE021985 · NIDCR · UNIVERSITY OF ROCHESTER · PI OVITT, CATHERINE, YULE, DAVID I · 2011 to 2021
$5.6M
Antibacterial inhibitors of RnpAR01AI134685 · NIAID · UNIVERSITY OF ROCHESTER · PI DUNMAN, PAUL M. · 2018 to 2022
$3.6M
NIAID NIH HHS R01 AI134685NIAMS NIH HHS P50 AR072000NIDCR NIH HHS T90 DE021985
6 · The paper itself

Abstract

Acinetobacter baumannii is a nosocomial pathogen of urgent concern for public health due to rising rates of multidrug and pandrug resistance. In the context of environmental cues such as growth in human serum, A. baumannii is known to display adaptive efflux, in which a multitude of efflux-associated genes are upregulated, resulting in efflux-mediated drug tolerance in strains that are otherwise susceptible to antibiotic therapy. Previously, we identified a sulfonamide-containing scaffold molecule (ABEPI1) that reversed serum-associated antibiotic tolerance in A. baumannii. Herein, we present structure-activity relationship studies on 29 newly synthesized analogues. These molecules were characterized for their ability to potentiate multiple antibiotics in serum, reduce serum-associated ethidium bromide efflux and depolarize bacterial cell membranes. In addition, they were assessed for toxicity to mammalian cells. Collectively, these molecules may represent promising potential adjuvants for use in combination with new and existing antibiotics to treat A. baumannii bacterial infections.

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsDose-Response Relationship, DrugDrug Resistance, Multiple, BacterialDrug ToleranceHep G2 CellsHumansMicrobial Sensitivity TestsMolecular StructureStructure-Activity RelationshipSulfonamidesAcinetobacter baumannii efflux pump inhibitor 1Anti-Bacterial AgentsSulfonamidesAcinetobacter baumanniiantibiotic resistanceefflux-pump inhibitors

Identifiers

PMID32681604
PMCPMC7899150
OpenAlexW3042339658

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.